Kymera Therapeutics, Inc. (KYMR) Fair Value 2026

KYMR · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.5 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (22/100)

Quick Summary — As of 2026-08-28, Kymera Therapeutics, Inc. (KYMR) trades at $118.15. QOC: 6.5/10. Value Trap Risk: 22/100 (SAFE). 0/13 models active.

Key Facts

Ticker
KYMR
Price
$118.15
Quality Score
6.5/10
Value Trap Risk
22/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Limited model coverage (0/13) may reduce confidence

What Fair Value Does Each Model Give KYMR?

0 Intrinsic Value Models vs. Current Price ($118.15)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Kymera Therapeutics, Inc. (KYMR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Kymera Therapeutics, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About KYMR?

0 of 13 models are currently active for KYMR. See which stocks rank higher →

How Does KYMR Rank in Biotechnology?

Among 625 Biotechnology stocks, KYMR ranks #98 by Quality of Company score. CirclFi's QOC score of 6.5/10 evaluates 32 fundamental signals. A score of 6.5 indicates above-average quality.

See all Most Undervalued Biotechnology Stocks →

As a biotechnology enterprise, Kymera Therapeutics, Inc. operates in a sector where pipeline depth and stage distribution is a critical driver of valuation. Investors evaluating KYMR should weigh these sector-specific dynamics alongside our model-derived fair values.

Is KYMR a Value Trap?

CirclFi's Value Trap algorithm assigns KYMR a score of 22/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Kymera Therapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Kymera Therapeutics, Inc.'s fundamental quality profile registers 6.5/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every KYMR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Kymera Therapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

VRDNViridian Therapeutics, Inc.QOC 6.5RAREUltragenyx Pharmaceutical Inc.QOC 6.4IMCRImmunocore Holdings plcQOC 6.5PTGXProtagonist Therapeutics, Inc.QOC 6.4CRSPCRISPR Therapeutics AGQOC 6.5TRAWTraws Pharma, Inc.QOC 6.4CAMPCAMP4 THERAPEUTICS CORPORATIONQOC 5.3INABIN8bio, Inc.QOC 4.6HEPAHepion Pharmaceuticals, Inc.QOC 3.6EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: VRDN · RARE · IMCR · PTGX · CRSP · TRAW · CAMP · INAB · HEPA · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to KYMR?

7 companies across all industries closest to KYMR’s Quality of Company score of 6.5/10.

VNCEVince Holding Corp.QOC 6.5ZHZhihu Inc.QOC 6.5TNDMTandem Diabetes Care, Inc.QOC 6.5SQFTPresidio Property Trust, Inc.QOC 6.4MNTKMontauk Renewables, Inc.QOC 6.5SAILSailPoint, Inc.QOC 6.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: VNCE · ZH · TNDM · SQFT · MNTK · SAIL · NVDA

Where Does KYMR Sit in CirclFi's Biotechnology Rankings?

KYMR is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Kymera Therapeutics, Inc.’s Valuation?

What is Kymera Therapeutics, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Kymera Therapeutics, Inc. (KYMR). The Quality of Company score is 6.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is KYMR overvalued or undervalued right now?

At $118.15, 0 of 0 active models suggest KYMR may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Kymera Therapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 6.5 mean for KYMR?

Kymera Therapeutics, Inc.'s QOC of 6.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on KYMR?

CirclFi analyzes KYMR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is KYMR a value trap in 2026?

Kymera Therapeutics, Inc.'s Value Trap score is 22/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Kymera Therapeutics, Inc. (KYMR) a Quality of Company score of 6.5/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/KYMR/ · Methodology
Primary sources for this KYMR valuation
  • Financial statements: Kymera Therapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001815442) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for KYMR as of ; valuations recomputed .